![John Wagner](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
John Wagner
Direktor/Vorstandsmitglied bei Stargazer Pharmaceuticals, Inc.
Ursprung des Netzwerks ersten Grades von John Wagner
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Stargazer Pharmaceuticals, Inc.
![]() Stargazer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Stargazer Pharmaceuticals, Inc. manufactures pharmaceutical products. The firm engages in the development of treatment for Stargardt’s disease, a rare form of juvenile, retinal degeneration. The company was founded by Gary Jay Sternberg and is headquartered in Boston, MA.
5
| Holding Company | Pharmaceuticals: Major | 5 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von John Wagner
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
Millennium Pharmaceuticals, Inc.
![]() Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Stanford University | College/University | Doctorate Degree | |
University of Pennsylvania | College/University | Undergraduate Degree | |
TAKEDA PHARMACEUTICAL COMPANY LIMITED | Pharmaceuticals: Major | Corporate Officer/Principal | |
BIOINVENT INTERNATIONAL AB | Biotechnology | Director/Board Member | |
Novo Holdings AS (Denmark)
![]() Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Financial Conglomerates | Chief Investment Officer | |
University of Oxford | College/University | Undergraduate Degree | |
University of Cambridge | College/University | Masters Business Admin | |
DuPont Merck Pharmaceutical Co.
![]() DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Pharmaceuticals: Major | Corporate Officer/Principal | |
King's College (Pennsylvania) | College/University | Undergraduate Degree | |
University College London | College/University | Doctorate Degree | |
Forbion Capital Partners Management Holding BV
![]() Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor | |
Cancer Research UK
![]() Cancer Research UK Miscellaneous Commercial ServicesCommercial Services Cancer Research UK provides cancer research services. It supports and undertakes research on the biology and causes of cancer and develops anti-cancer drugs. The firm also provides general information about cancer and types of treatments and funds projects that help patients cope with the side effects of cancer and its treatment. Its institute also operates an online portal CancerHelp UK that provides patient information. The company was founded in 2001 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Novo Ventures 1 A/S
![]() Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Investment Managers | Private Equity Investor Corporate Officer/Principal | |
venBio Partners LLC
![]() venBio Partners LLC Investment ManagersFinance venBio Partners LLC (venBio) is a venture capital subsidiary of Venbio Partners LP founded in 2009 by Adelman robert and Goodman corey. The firm is headquartered in San Francisco, California. | Investment Managers | Private Equity Investor | |
ORPHAZYME A/S | Pharmaceuticals: Major | Director/Board Member | |
Pcovery ApS
![]() Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
Epsilon-3 Bio Ltd
![]() Epsilon-3 Bio Ltd Pharmaceuticals: OtherHealth Technology Epsilon-3 Bio Ltd. develops compounds targeting the removal of cellular debris in chronic inflammatory and autoimmune disorders. The company was founded by Martin W. Edwards, Konstantinos Efthymiopoulos, David J. Grainger and Christian De La Tour on June 18, 2010 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Other | Founder Director/Board Member | |
Galecto Biotech ApS
![]() Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Avilex Pharma ApS
![]() Avilex Pharma ApS Pharmaceuticals: MajorHealth Technology Avilex Pharma ApS develops and produces drugs to treat brain damage with the uses of dimeric ligands. It also develops novel inhibitors to target a range of unmet medical needs. The firm uses dimeric ligands that targets intracellular with unprecedented potency. The company was founded by Kristian Strømgaard and Anders Bach on December 27, 2012 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
OBSEVA SA | Pharmaceuticals: Major | Director/Board Member | |
Numab Therapeutics AG
![]() Numab Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland. | Miscellaneous Commercial Services | Director/Board Member | |
The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin | |
NBE-Therapeutics AG
![]() NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland. | Biotechnology | Director/Board Member | |
University of Pennsylvania Medical Center | College/University | Doctorate Degree | |
Glionova AB
![]() Glionova AB Pharmaceuticals: MajorHealth Technology Glionova AB develops cancer treatment drugs. The firm is a drug discovery and development company. It offers GLN-1001 product. The company was founded by Lars G. J. Hammarström and Patrik Ernfors in 2014 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
Inthera Bioscience AG
![]() Inthera Bioscience AG BiotechnologyHealth Technology Inthera Bioscience AG engages in the research in as well as development, production, and distribution of pharmaceutical, biological, and other products used in the fields of human and veterinary medicine. It also provides related consultancy services. The company was founded by Ulrich Kessler and Paramjit Singh Arora on September 20, 2013 and is headquartered in Zurich, Switzerland. | Biotechnology | Director/Board Member | |
PLIANT THERAPEUTICS, INC. | Biotechnology | Corporate Officer/Principal | |
ReViral Ltd.
![]() ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | Biotechnology | Director/Board Member | |
PHARVARIS N.V. | Pharmaceuticals: Major | Director/Board Member | |
IO Biotech ApS
![]() IO Biotech ApS BiotechnologyHealth Technology IO Biotech ApS operates as a clinical stage biotech company. It develops immunotherapy for cancer by targeting a mechanism used by tumour cells to evade immune responses. The company was founded by Mai-Britt Zocca, Mads Hald Andersen, Inge Marie Svane, Anders Ljungqvist and Per Thor Straten and is headquartered in Copenhagen, Denmark. | Biotechnology | Director/Board Member | |
INVENTIVA | Biotechnology | Director/Board Member | |
XILIO THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Snoody Ltd.
![]() Snoody Ltd. Medical SpecialtiesHealth Technology Snoody Ltd. develops and supplies antiviral and healing technology for various product applications. It provides wound dressings, mastitis prevention products, ulcer preventing socks, face masks, and integrated pathogen defense products. The company was founded in 2009 by Paul Francis Hope and is headquartered in Manchester, the United Kingdom. | Medical Specialties | Founder | |
Arrakis Therapeutics, Inc.
![]() Arrakis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arrakis Therapeutics, Inc. operates as a biopharmaceutical company. It develops rna-targeted small molecule medicines focused on neurologic, cancer, and rare genetic diseases. The company was founded by Russell C. Petter, Alan E. Walts, Jennifer C. Petter and Raj Bhikhu Parekh in 2015 and is headquartered in Waltham, MA. | Pharmaceuticals: Major | Director/Board Member | |
Aeovian Pharmaceuticals, Inc.
![]() Aeovian Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aeovian Pharmaceuticals, Inc. engages in the development of pharmaceuticals. It offers inhibitors for the treatment of rare and age-related diseases. The company was founded by Stelios T. Tzannis in 2012 and is headquartered in Novato, CA. | Pharmaceuticals: Major | Director/Board Member | |
NorthSea Therapeutics BV
![]() NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | Biotechnology | Director/Board Member | |
LAVA THERAPEUTICS N.V. | Biotechnology | Director/Board Member | |
NodThera Ltd.
![]() NodThera Ltd. BiotechnologyHealth Technology NodThera Ltd. researches and develops novel inhibitors of the NLRP3 inflammasome. The company is headquartered in Little Chesterford, the United Kingdom. | Biotechnology | Director/Board Member | |
Inversago Pharma, Inc.
![]() Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Inversago Pharma, Inc. develops novel gastrointestinal drugs. The company was founded by Fran?ois Ravenelle in and is headquartered in Montreal, Canada. | Pharmaceuticals: Major | Director/Board Member | |
VENTYX BIOSCIENCES, INC. | Biotechnology | Director/Board Member | |
ELEVATION ONCOLOGY, INC. | Biotechnology | Director/Board Member | |
Attralus, Inc.
![]() Attralus, Inc. Pharmaceuticals: MajorHealth Technology Attralus, Inc. operates as a biopharmaceutical company. The firm focuses on illuminating the systemic nature of amyloidosis and creating transformative medicines to improve the lives of patients. The company was founded by Jonathan Wall in 2019 and is headquartered in San Francisco, CA. | Pharmaceuticals: Major | Director/Board Member | |
Pharvaris GmbH
![]() Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
Locki Therapeutics Ltd.
![]() Locki Therapeutics Ltd. BiotechnologyHealth Technology Locki Therapeutics Ltd. is a British preclinical stage biotechnology company founded in 2019. The company is based in London, UK. Locki Therapeutics is developing a new class of drugs that enhance the function of beneficial proteins. The company has designed its proprietary encompass™ platform to create enhancement-targeting chimeric (entac™) medicines. These entacs harness the ability of dubs to regulate proteins, expanding the universe of treatable diseases. | Biotechnology | Director/Board Member | |
Tome Biosciences, Inc.
![]() Tome Biosciences, Inc. BiotechnologyHealth Technology Tome Biosciences, Inc. provides genomic medicine insertion and technologies services. The company is based in Cambridge, MA. The CEO of the company is Rahul Kakkar. | Biotechnology | Director/Board Member | |
Oak Hill Bio Corp.
![]() Oak Hill Bio Corp. Miscellaneous Commercial ServicesCommercial Services Oak Hill Bio, Inc. is a clinical-stage rare disease therapeutics company. It develops life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases. The firm has operations in the United States and United Kingdom to develop a pipeline of clinical-stage and pre-clinical investigational therapeutics acquired and licensed from Takeda Pharmaceutical Company Limited. The company is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Director/Board Member | |
35Pharma, Inc.
![]() 35Pharma, Inc. Pharmaceuticals: MajorHealth Technology 35Pharma, Inc. designs and develops biologics for diseases of high unmet medical need. The CEO of the Canadian company is Ilia A. Tikhomirov. | Pharmaceuticals: Major | Director/Board Member | |
Affinicon ApS
![]() Affinicon ApS Pharmaceuticals: MajorHealth Technology Affinicon ApS operates as a biotechnology company. It develops combinatory drugs for treatment of diseases such as inflammation, infections, and certain forms of cancer. The firm exploits a novel platform technology for targeted delivery of known drugs to macrophages. The company was founded by Niels Jonas Heilskov Graversen on July 4, 2013 and is headquartered in Aarhus, Denmark. | Pharmaceuticals: Major | Director/Board Member |
Statistik
International
Vereinigte Staaten | 17 |
Vereinigtes Königreich | 12 |
Dänemark | 9 |
Schweiz | 6 |
Niederlande | 4 |
Sektoral
Health Technology | 36 |
Consumer Services | 9 |
Finance | 5 |
Commercial Services | 4 |
Operativ
Director/Board Member | 59 |
Corporate Officer/Principal | 15 |
Independent Dir/Board Member | 8 |
Chairman | 5 |
Chief Executive Officer | 5 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Martin Edwards | 38 |
Nanna Liebach Lüneborg | 29 |
Richard Gaster | 17 |
Daniel Curran | 10 |
Gary Jay Sternberg | 9 |
- Börse
- Insiders
- John Wagner
- Unternehmensverbindungen